Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969056 | 0.79 | KMT2A (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL753480 | 0.77 | — | — | |
| SCHEMBL5600137 | 0.76 | PDE5A (0.40) | MEN1KMT2AKDM4E | |
| SCHEMBL8086941 | 0.71 | CYP4F2 (0.45) | ALDH1A1HSD17B10CYP4F2CYP4A11MEN1 | |
| SCHEMBL5672910 | 0.69 | MAPK1 (0.47) | ALDH1A1SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL15725258 | 0.69 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL743243 | 0.68 | — | — | |
| SCHEMBL15709932 | 0.68 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2RAB9ANPC1TP53 | |
| SCHEMBL972652 | 0.68 | — | — | |
| SCHEMBL9709994 | 0.68 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2RAB9ANPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063061-B2 | 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites | SANOFI-AVENTIS (FR) | 2011-11-22 | — | — | US | claimed |
| EP-1940840-B1 | 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-21 | — | — | EP | claimed |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | claimed |
| CN-102947311-B | 3-oxo-3, 9-dihydro-1H-benzopyrano [2,3-C ] pyrroles as glucokinase activators | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | disclosed |
| CN-102007118-B | Pyrrolidinone glucokinase activators | HOFFMANN LA ROCHE | 2014-12-31 | — | — | CN | disclosed |
| CN-102007116-B | Pyridazinone glucokinase activators | HOFFMAN-LA ROCHE LTD. (CH) | 2014-10-22 | — | — | CN | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2582706-A1 | 3-OXO-3,9-DIHYDRO-1H-CHROMENO[2,3-C]PYRROLES AS GLUCOKINASE ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| CN-102947311-A | 3-oxo-3, 9-dihydro-1H-benzopyrano [2,3-C ] pyrroles as glucokinase activators | HOFFMANN LA ROCHE | 2013-02-27 | — | — | CN | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| CN-102791131-A | Compounds and methods | GLAXOSMITHKLINE LLC | 2012-11-21 | — | — | CN | disclosed |
| US-20070093507-A1 | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | LAMBROU GEORGE N | 2007-04-26 | — | — | US | disclosed |
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1663230-A1 | COMPOSITIONS COMPRISING BENZO(G)QUINOLINE DERIVATIVES AND PROSTAGLANDIN DERIVATIVES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| EP-1618096-A1 | 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS | Novartis AG (CH) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005023258-A1 | COMPOSITIONS COMPRISING BENZO (G) QUINOLINE DERIVATIVES AND PROSTAGLANDIN DERIVATIVES | NOVARTIS AG (CH) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004089916-A1 | 11-PHENYL-DIBENZODIAZEPINE DERIVATIVES AS RXR-ANTAGONISTS | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-6080743-A | AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS | NOVARTIS AG (CH) | 2000-06-27 | — | — | US | disclosed |
| EP-0853617-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | Novartis AG (CH) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997008155-A1 | NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES | NOVARTIS AG (CH) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043029-A1 | 11-Phenyl-dibenzodiazepine derivatives as rxr-antagonists | RXRB, RXRA, RXRG | ALDH1A1 2952/4885SMN1; SMN2 2655/4885RAB9A 1436/4885 |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | ALDH1A1 902/4885SMN1; SMN2 2275/4885RAB9A 3528/4885 |
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | ALDH1A1 555/4885SMN1; SMN2 2641/4885RAB9A 651/4885 |
| US-20070093507-A1 | Compositions comprising benzo (g) quinoline derivatives and prostaglandin derivatives | PTGIS, PTGES, PTGS2 | ALDH1A1 1871/4885SMN1; SMN2 4712/4885RAB9A 1965/4885 |
| US-20080262020-A1 | 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof | CYP11B2, CYP11B1, CYP2D6 | ALDH1A1 283/4885SMN1; SMN2 3153/4885RAB9A 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.